Recombinant erythropoietin in clinical practice

T Ng, G Marx, T Littlewood, I Macdougall

The introduction of recombinant human erythropoietin (RHuEPO) has revolutionised the treatment of patients with anaemia of chronic renal disease. Clinical studies have demonstrated that RHuEPO is also useful in various non-uraemic conditions including haemato logical and oncological disorders, prematurity, HIV infection, and perioperative therapies. Besides highlighting both the historical and functional aspects of RHuEPO, this review discusses the applications of RHuEPO in clinical practice and the potential problems of RHuEPO treatment.

The human body generates 2.5 million new red blood cells (RBCs) per second from the bone marrow to replenish the continuous removal of effete RBCs. The production of RBCs (erythropoiesis) is controlled by an intricate interaction between various humoral factors and cytokines. A specific cytokine, a sialoglycoprotein known as erythropoietin, which acts directly on certain RBC progenitors and precursors in the bone marrow, controls the proliferation, differentiation, and maturation of RBCs. The expression of erythropoietin is markedly increased in kidneys during hypoxic state, a condition mediated by the transcription factor HIF-1. The ultimate effect is to increase erythropoiesis in an attempt to maintain oxygen delivery to vital organs. This article provides an overview of erythropoietin on both historical and scientific aspects, followed by a discussion of its current and potential applications in clinical medicine.

HISTORICAL PERSPECTIVE
From observation to discovery
A positive correlation of hypoxia and anaemia with erythrocytosis has been noticed through clinical observations and experiments since the late 19th century (table 1). Nevertheless, the purification of erythropoietin has been difficult because of technical limitations, heterogeneity of target cell population, and insufficient quantity of erythropoietin available for further analysis. A major breakthrough occurred in 1977 when Miyake and coworkers successfully purified and characterised human erythropoietin from urine of patients with aplastic anaemia. In 1985, two groups of investigators independently cloned the human erythropoietin gene with the identification of the corresponding nucleotide sequences.

From discovery to clinical practice
Before the availability of recombinant human erythropoietin (RHuEPO), the only treatment for patients with anaemia of chronic renal failure was blood transfusion. Unfortunately, blood transfusion had to be given regularly so as to maintain the haemoglobin level. Furthermore, various transfusion related problems, in particular iron overload, significantly compromised the management and outcome of renal patients. Based on the promising results on animal models, erythropoietin was considered a prime candidate as replacement therapy. As soon as RHuEPO was made available for human trial, a series of clinical studies were promptly conducted to assess its effectiveness in correcting anaemia of chronic renal disease. The initial results demonstrated that RHuEPO could restore the packed cell volume, abrogate the necessity of regular blood transfusion in patients requiring dialysis, and improve the overall wellbeing. The results of these trials were so impressive that RHuEPO was granted a licence as a therapeutic agent in 1988 for patients with anaemia of chronic renal failure, only three years after its discovery.

RECOMBINANT HUMAN ERYTHROPOIETIN
Structural and biological characteristics
Erythropoietin in blood is mainly of renal origin, with a small amount derived from the liver. The human erythropoietin gene is situated at chromosome 7q11-22, consisting of five exons and four introns, which produces a post-transcriptional single polypeptide containing 193 amino acids. During the post-translational modification, glycosylation occurs with the addition of three N-linked (at Asn-24, Asn-38 and Asn-83) and one O-linked (at Ser-126) acidic oligosaccharides, the formation of two disulphide bonds at Cys-7 to Cys-161 and at Cys-29 to Cys-33, concomitant with the removal of the 27 amino acid hydrophobic secretory sequence. The Arg-166 at the COOH terminal is believed to be cleaved before the release of erythropoietin into the circulation, with the primary structure of a mature erythropoietin (and hence RHuEPO) containing 165 amino acids (fig 1). The molecular mass of the polypeptide backbone and the glycosylated form of erythropoietin is estimated to be 18 kDa and 30 kDa respectively. Circular dichroism spectral analysis has proposed that its secondary structure contains 50% of α-helix moiety, with spatial arrangement of two α-helical pairs running antiparallel.

Abbreviations:
- CSF, granulocyte colony-stimulating factor
- NESP, novel erythropoiesis stimulating protein
- PRCA, pure red cell aplasia
- RBCs, red blood cells
- RHuEPO, recombinant human erythropoietin

Please note that packed cell volume is used in the text; this is equivalent to haematocrit.
similar to that of growth hormone. The glycosylated (or sugar) moiety of erythropoietin has an important role in terms of biosynthesis, tertiary structure of the molecule, and in vivo biological activity.

The N-glycosylated moiety of RHuEPO has three main functional units: the main core, the branched portion and the terminal component, with each unit having a specific role (fig 2). The function of the O-glycosylated unit, a component constituting about 3% of the total mass of RHuEPO, remains to be defined.

There are currently four different RHuEPOs: alpha, beta, delta, and omega. However, only EPO-alpha and EPO-beta are

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Historical perspective of erythropoietin (EPO), adapted from Jelkmann¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributors</td>
<td>Contributions</td>
</tr>
<tr>
<td>Bert (1882)</td>
<td>Observation of increased RBC count at high altitude</td>
</tr>
<tr>
<td>Vaulot (1890)</td>
<td>Experiment on injected blood from anaemic rabbits to donor rabbits causing a 20%–40% increased RBC in blood</td>
</tr>
<tr>
<td>Miescher (1890)</td>
<td></td>
</tr>
<tr>
<td>Carnot and Deflandre (1906)</td>
<td>Experiment on injected blood from hypoxic rabbits to donor rabbits causing an increased RBC in blood</td>
</tr>
<tr>
<td>Muller (1912)</td>
<td></td>
</tr>
<tr>
<td>Sandor (1932)</td>
<td></td>
</tr>
<tr>
<td>Krumdieck (1943)</td>
<td></td>
</tr>
<tr>
<td>Bonsdorff and Jalavisto (1948)</td>
<td>Experiment on injected blood from hypoxic animals to untreated animals causing a raised RBC production</td>
</tr>
<tr>
<td>Reissmann (1950)</td>
<td>Increased RBC production on parabiotic animals when hypoxia and anaemia was introduced in one of them</td>
</tr>
<tr>
<td>Ruhenstroth-Bauer (1950)</td>
<td>Repeated infusing plasma from severely anaemic rabbits to donor rabbits causing increased packed cell volume/reticulocyte count</td>
</tr>
<tr>
<td>Hodgson and Toha (1954)</td>
<td>EPO activity isolated in urine and plasma of anaemic rabbits</td>
</tr>
<tr>
<td>Stohlman et al (1954)</td>
<td>Observations of RBC hyperplasia in bone marrow in patients with patent duc tus arteriosus</td>
</tr>
<tr>
<td>Schmid and Gilbert (1955)</td>
<td></td>
</tr>
<tr>
<td>Jacobson et al (1957)</td>
<td>No increase in RBC in nephrectomised animals</td>
</tr>
<tr>
<td>Fisher and Birdwell (1961)</td>
<td></td>
</tr>
<tr>
<td>Fischer et al (1965)</td>
<td>Localisation of EPO production to renal glomeruli</td>
</tr>
<tr>
<td>Frenkel et al (1968)</td>
<td></td>
</tr>
<tr>
<td>Katz et al (1968)</td>
<td>Detection of EPO activity in liver</td>
</tr>
<tr>
<td>Fried (1972)</td>
<td></td>
</tr>
<tr>
<td>Essers et al (1974)</td>
<td>Suggested liver being insufficient to replace kidney for EPO production</td>
</tr>
<tr>
<td>Miyake et al (1977)</td>
<td>Purification of EPO from urine in patients with aplastic anaemia</td>
</tr>
<tr>
<td>Arangio et al (1977)</td>
<td>EPO on animals with anaemia of renal failure</td>
</tr>
<tr>
<td>Van Stone and Max (1979)</td>
<td></td>
</tr>
<tr>
<td>Lin et al (1985)</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1  | Primary structure of erythropoietin (hence RHuEPO).<sub>1</sub> | [CH]₄, N-linked glycosylation site at asparyl residues 24, 38, 83; [CH]₆, O-linked glycosylation site at seryl residue 126. NB: The ARG-166 at the carboxyl terminal is removed before erythropoietin is released into the circulation. |
commercially available in the UK at the moment. Although these RHuEPOs act on the same erythropoietin receptor, there are some variations on the degree of glycosylation which lead to the differences in the pharmacokinetics and pharmacodynamics among the RHuEPOs.

**Modifications of RHuEPO**

As the N-glycosylation confers the biological activity of RHuEPO, an increase in the number of glycosylation sites may enhance its activity. A hyperglycosylated RHuEPO, known as NESP (novel erythropoiesis stimulating protein; Darbepoetin-alpha) has recently been introduced. By using a process called “site mutagenesis”, the polypeptide backbone of the RHuEPO is modified, leading to the creation of five N-glycosylation sites (compared with three in RHuEPO).

Compared with the RHuEPOs, NESP has a higher negative charge and a threefold longer half life. It requires a less frequent dosing schedule and produces a similar clinical outcome and safety profile as RHuEPOs in treating anaemia of chronic renal disease and of malignancy. Compared with the RHuEPOs, NESP has a higher negative charge and a threefold longer half life. It requires a less frequent dosing schedule and produces a similar clinical outcome and safety profile as RHuEPOs in treating anaemia of chronic renal disease and of malignancy. Compared with the RHuEPOs, NESP has a higher negative charge and a threefold longer half life. It requires a less frequent dosing schedule and produces a similar clinical outcome and safety profile as RHuEPOs in treating anaemia of chronic renal disease and of malignancy.

**Mechanism of action**

Erythropoietin is essential for the proliferation, differentiation, and maturation of RBCs in bone marrow and may also have immunomodulatory activity. Erythropoietin functions by binding to the erythropoietin receptor: a 72–78 kDa glycosylated and phosphorylated transmembrane polypeptide. The erythropoietin receptor is a member of the superfamily of cytokine receptors. The number of erythropoietin receptors varies during RBC differentiation, with its peak presentation at the colony forming unit-erythroid/proerythroblastic stage and the level being undetectable at the reticulocytes.

**ADMINISTRATION OF RHU EPO**

**Route of administration**

Both intravenous and subcutaneous administrations are commonly used to deliver RHuEPO to renal patients. Clinical studies have demonstrated that the subcutaneous route offers a few advantages over intravenous administration. For instance, subcutaneous administration is more convenient as it does not require any venous access. When compared with
Patients at pre-dialysis stage
A review published in 1995 suggested that pre-dialysis patients (and those with failing renal allografts) would gain no benefit from RHuEPO therapy if glomerular filtration rate was less than 15 ml/min but there would be a risk of accelerating to end stage renal failure.15 However, recent clinical studies have failed to confirm these negative effects of RHuEPO.16 In fact, a meta-analysis on published data involving 12 randomised studies with more than 200 pre-dialysis patients during the period 1980–2001 has shown that early treatment with RHuEPO corrected anaemia, avoided blood transfusion, and improved the quality of life and exercise capacity.17 Although there was an increase in the requirement for antihypertensive therapy, no statistically significant increase in adverse events was otherwise found. There was also no evidence to suggest that RHuEPO therapy hastened a deterioration of renal function, though the authors conceded that the duration of RHuEPO therapy in most of the trials might not be long enough to confirm the benefit. Early application of RHuEPO has been shown to reduce the risk of cardiovascular events and the associated mortality.18 The addition of intravenous iron may decrease the dosage requirement of RHuEPO and could provide an additive and rapid effect in the correction of renal anaemia during the pre-dialysis period.14

Patients with renal transplant
Unfortunately, there are insufficient clinical data to discuss in details the use of RHuEPO in the transplant setting. The avoidance of pre-transplant blood transfusion may impair the success of graft survival in patients receiving a cadaveric transplant, according to collaborative transplant studies.21 Furthermore, there are concerns that an increase in packed cell volume during renal transplant may predispose the patient to develop graft thrombosis and delayed graft function.22 23 Muirhead reviewed the current data and highlighted several issues.24 Firstly, there was no convincing evidence of delayed graft function or graft thrombosis in patients previously treated with RHuEPO. Secondly, the use of RHuEPO might reduce allosensitisation as a result of random blood transfusion while allowing the benefits of graft survival from deliberate transfusion. Thirdly, the correction of post-transplant anaemia was enhanced and hastened by RHuEPO therapy. Fourthly, the effect of RHuEPO was minimal during an acute episode of graft rejection but its benefit resumed once successful treatment of the rejection episode had been achieved. Finally, despite the use of immunosuppressants, patients with failing grafts had a similar response to RHuEPO compared with those on dialysis. A recent study in Sweden has shown that pre-transplant correction of haemoglobin reduced the necessity of postoperative blood transfusion with no evidence of worsening the transplant outcome.25

Anaemia of prematurity
Neonates born prematurely (before 32 weeks of gestation) weighing less than 1300 g usually receive multiple blood transfusions to compensate for regular blood sampling required for intensive monitoring, along with a physiologically low serum level of erythropoietin. The principle of using RHuEPO in this setting, as replacement therapy, is to minimise the amount of blood transfused. Despite more than 12 clinical studies, involving more than a thousand premature

Box 2: Clinical applications of RHuEPO

- Replacement therapy (low endogenous erythropoietin level) in anaemia associated with:
  - Chronic renal failure.
  - Malignancy.
  - Prematurity.
  - HIV infection.
- Supportive therapy (to maintain/accelerate erythropoiesis) in:
  - Post-chemotherapy/post-radiotherapy.
  - Post-transplantation.
- Augmentative therapy (increase haemoglobin above physiological level) in:
  - Surgery.
  - Situations where blood transfusion is refused/disallowed.
  - Sport (potential abuse by athletes).
- To enhance autologous transfusion so as to maintain haemoglobin peripheratively.
- Potential therapeutic applications:
  - Anaemia associated with—autoimmune diseases, acute haemolysis, haemoglobinopathy.
  - Acute renal failure.
  - Critically ill patients.
  - Neuroprotection.
  - Congestive cardiac failure.
Anaemia associated with malignancy

Anaemia is a complication commonly encountered in malignancy, especially of haematological origin, either at presentation or during the course of treatment. Anaemia of chronic disease, a condition characterised by disordered iron metabolism, shortened RBC half life and inefficient erythropoiesis, is the major contributor to cancer anaemia.57 Besides impovertising the patient’s quality of life, anaemia at diagnosis is a poor prognostic factor (especially in lymphoproliferative disorders) and may affect the outcome of radiotherapy treatment. Although blood transfusion remains the mainstay of treatment for symptomatic anaemia, it is associated with various problems. Firstly, oxygen delivery by preserved RBCs decreases after one week of storage as a result of decrease in 2,3-diphosphoglycerate levels in RBCs causing a right shift in the oxygen dissociation curve.67 The latter result could be related to the increase in natriuretic peptides that benefit significantly from RHuEPO therapy, with an average response rate of 60%. Whether RHuEPO is given as supportive (post-chemotherapy), preventive (pre-treatment) or maintenance (optimisation of haemoglobin while not on treatment) therapy, it increases the haemoglobin and minimises the requirement for blood transfusions.67 However, a delay in treatment response of up to four weeks may occur.

Although the response rate of myelodysplastic syndrome to RHuEPO therapy is approximately 20%, the addition of granulocyte colony-stimulating factor (G-CSF) has been shown to improve the response. The response to the combined cytokine treatment is not significantly correlated with the type of myelodysplastic syndrome, age or sex of the patient. Treatment is usually well tolerated and there is no evidence of an increased risk of leukaemic transformation.68 Hellstrom-Lindberg and coworkers proposed a model to predict the response of anaemia to combined RHuEPO and G-CSF.69 The authors introduced a scoring system based on two main criteria: the level of serum erythropoietin before treatment and the transfusion requirement per month. Using these criteria, three response groups were generated: high, intermediate, and low with the corresponding predicted response rate to RHuEPO therapy of 74%, 23%, and 7% respectively. A long term response could be achieved in up to one third of patients and a dose of 20 000 U/week appeared to be an effective maintenance dose of RHuEPO treatment.

Anaemia associated with bone marrow/stem cell transplantation

“Conditioning” using intensive chemotherapy with or without radiotherapy (myeloablative treatment) before transplantation induces a state of pancytopenia which requires regular blood product support until bone marrow/stem cells have been fully engrafted. The frequency of blood transfusion requirement has been estimated at 11/patient/50 kg body weight within the first two months after transplant. This may be further increased if complications such as immune haemolysis, graft-versus-host disease, or bleeding occur.70 Impaired production of erythropoietin (for example, renal damage due to chemotherapy, inhibition of erythropoietin secretion by amphotericin treatment) and a blunted response to erythropoietin (for

infants, no conclusion could be made as whether RHuEPO could definitively reduce the requirements for blood transfusion.71 Nevertheless, when the results from those infants were selectively analysed, it appeared that only those infants who received ≥600 IU/kg/week required less frequent blood transfusion. Economic analysis has shown that in those premature neonates who required transfusion, the use of RHuEPO would be cost effective and cost beneficial only if the administration of RHuEPO reduced the rate of transfusion.72 It is interesting to note that preterm infants receiving RHuEPO may have a lower incidence of necrotising enterocolitis72 and a reduction in the number of days requiring oxygen support.73 The latter result could be related to the increase in 2,3-diphosphoglycerate levels in RBCs causing a right shift in the oxygen dissociation curve.73

When RHuEPO is applied before chemotherapy, it prevents the decline in haemoglobin and decreases the requirement of blood transfusion during the course of chemotherapy.74 Nowroussian has suggested that when given subcutaneously at a dose of 150 IU/kg three times a week in selected patients, RHuEPO can produce a response rate of up to 80%.75 In a large prospective community study, the use of RHuEPO increased the functional capacity and the quality of life of patients. It also improved the level of haemoglobin and minimised blood transfusion requirements.76 The positive outcomes correlated with the haemoglobin level but were independent of the tumour response.

Recent clinical studies have demonstrated that a normal or near normal level of haemoglobin before radiotherapy with or without chemotherapy could improve the treatment outcome.77 In a recent multicentre, randomised study in patients with pelvic malignancies, the addition of RHuEPO to the treatment course of radiotherapy improved both treatment response rate and patients’ survival.78 Furthermore, a recent analysis of two large scale studies involving 4382 patients, has revealed that patients with solid tumours receiving RHuEPO had a significant improvement in quality of life occurring between haemoglobin levels from 80 to 140 g/l.79 The most noticeable benefit, from an incremental increase in haemoglobin, occurred when there was a change in haemoglobin from 110 to 120 g/l.

Haematological malignancy/pre-leukaemic stem cell disorder

Multiple myeloma, lymphoproliferative diseases, and chronic lymphocytic leukaemia are those haematological disorders that benefit significantly from RHuEPO therapy, with an average response rate of 60%. Whether RHuEPO is given as supportive (post-chemotherapy), preventive (pre-treatment) or maintenance (optimisation of haemoglobin while not on treatment) therapy, it increases the haemoglobin and minimises the requirement for blood transfusions.76 However, a delay in treatment response of up to four weeks may occur.

Although the response rate of myelodysplastic syndrome to RHuEPO therapy is approximately 20%, the addition of granulocyte colony-stimulating factor (G-CSF) has been shown to improve the response. The response to the combined cytokine treatment is not significantly correlated with the type of myelodysplastic syndrome, age or sex of the patient. Treatment is usually well tolerated and there is no evidence of an increased risk of leukaemic transformation.78 Hellstrom-Lindberg and coworkers proposed a model to predict the response of anaemia to combined RHuEPO and G-CSF.79 The authors introduced a scoring system based on two main criteria: the level of serum erythropoietin before treatment and the transfusion requirement per month. Using these criteria, three response groups were generated: high, intermediate, and low with the corresponding predicted response rate to RHuEPO therapy of 74%, 23%, and 7% respectively. A long term response could be achieved in up to one third of patients and a dose of 20 000 U/week appeared to be an effective maintenance dose of RHuEPO treatment.
Table 2 Problems associated with allogeneic blood transfusion

<table>
<thead>
<tr>
<th>Problems</th>
<th>Estimated risk (per unit of blood transfused)*</th>
<th>Pathological basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate (within 24 hours)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1) Acute haemolysis (potentially fatal)</td>
<td>1:6000–800000</td>
<td>ABO incompatibility</td>
</tr>
<tr>
<td>(2) Bacterial infection (potentially fatal)</td>
<td>1:450–12500</td>
<td>Bacterial contamination</td>
</tr>
<tr>
<td>(3) Other immune related reaction:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Febrile non-haemolytic transfusion reaction</td>
<td>1:200</td>
<td>Sensitivity to WBC</td>
</tr>
<tr>
<td>Transfusion related acute lung injury (20% mortality)</td>
<td>1:5000–10000</td>
<td>Donor lymphocytes against recipient WBC with shared HLA haplotypes</td>
</tr>
<tr>
<td>(4) Volume overload</td>
<td>1:100–10000</td>
<td>Too rapid transfusion or in patients with pre-existing cardiac failure</td>
</tr>
<tr>
<td>Short term (within 4 days)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1) Volume overload</td>
<td>As previously stated</td>
<td>As previously stated</td>
</tr>
<tr>
<td>(2) Haemolysis (usually low grade but progressive)</td>
<td>1:183–4000</td>
<td>Delayed antibody reaction to RBC antigen (other than ABO), low grade bacterial infection</td>
</tr>
<tr>
<td>(3) RBC antigen sensitisation (allosensitisation)</td>
<td>1:100</td>
<td>RBC antigen (other than ABO) incompatibility</td>
</tr>
<tr>
<td>Intermediate (within 14 days)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1) RBC antigen sensitisation (allosensitisation)</td>
<td>As previously stated</td>
<td>As previously stated</td>
</tr>
<tr>
<td>(2) Haemolysis (usually low grade but progressive)</td>
<td>As previously stated</td>
<td>Delayed antibody reaction to RBC antigen (other than ABO)</td>
</tr>
<tr>
<td>(3) Increased risk of postoperative infection</td>
<td>N/A</td>
<td>Immuno modulation</td>
</tr>
<tr>
<td>(4) Post-transfusion purpura</td>
<td>Rare (1:200000)</td>
<td>Passive transfer of HPA platelet antibody from HPA antigen negative donor</td>
</tr>
<tr>
<td>Long term (&gt;14 days)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1) Increasing difficulty in cross matching</td>
<td>N/A</td>
<td>Previous allosensitisation of RBC antigen as a result of repeated transfusion</td>
</tr>
<tr>
<td>(2) Secondary iron overload</td>
<td>N/A</td>
<td>Due to repeated blood transfusion</td>
</tr>
<tr>
<td>(3) Transfusion related graft-versus-host disease (potentially fatal)</td>
<td>Rare (1:500000)</td>
<td>Donor immunoreactive lymphocytes against recipient HLA antigens (HLA incompatibility)</td>
</tr>
<tr>
<td>(4) Seroconversion of cytomegalovirus</td>
<td>1:14 – 41</td>
<td>Passive transfer of CMV infected WBCs</td>
</tr>
<tr>
<td>(5) Increased risk of malignancy</td>
<td>[&gt; 2 over life time]</td>
<td>? Immuno modulation</td>
</tr>
<tr>
<td>(6) New variant CJD</td>
<td>N/A</td>
<td>? WBC mediated</td>
</tr>
<tr>
<td>(7) Hepatitis B and C</td>
<td>Rare (1:200000)</td>
<td>Infected blood</td>
</tr>
<tr>
<td>(8) HIV</td>
<td>Very rare (&lt;1:3000000)</td>
<td>Infected blood</td>
</tr>
</tbody>
</table>

*Data obtained from various sources including non-filtered to leucodepleted blood.

---

Box 4: Key learning points

- Anaemia of chronic disease is the main cause of cancer anaemia.
- RHuEPO therapy corrects 50% of cancer anaemia in general.
- Treatment with RHuEPO minimises the transfusion requirement.
- Quality of life in cancer patients is enhanced with RHuEPO treatment.
- RHuEPO therapy improves both treatment outcome and survival of cancer patients.

---

example, tumour necrosis factors produced during inflammation) could also contribute to post-transplant anaemia. Klaesen reviewed 17 clinical trials of bone marrow/stem cell transplantation (11 allogeneic; seven autologous) using intravenous RHuEPO (range 50 U/kg three times a day to 500 U/kg once a day for a 28–30 day period), with or without G-CSF/granulocyte-macrophage-CSE. The author concluded that in patients receiving an allogeneic transplant, the use of RHuEPO could expedite erythroid engraftment and augment the level of haemoglobin. Furthermore, RHuEPO therapy could reduce the requirements for blood transfusion and hasten the time to transfusion independence. The efficacy of RHuEPO was also observed in late-onset anaemia due to graft-versus-host-disease or infection and immune haemolysis secondary to bone marrow/stem cell ABO incompatibility. Transplant donors pre-treated with RHuEPO (and iron supplement) did not require autologous blood transfusions. However, these benefits from RHuEPO treatment were not found in patients receiving an autologous transplant. The author has argued that despite these benefits, RHuEPO therapy costs an extra US$2000 (about £1334) to avoid five extra units of blood to be transfused. In the UK, the cost may be offset by the subcutaneous RHuEPO administration and by the expense incurred on the universal leucodepletion of blood products. The increased popularity of non-myeloablative approach of bone marrow/stem cell transplant (mini-transplant) may reduce the dosage requirement for RHuEPO. Further studies in this area are warranted.

Anaemia associated with surgery

Autologous transfusion, either as pre-donation (haemoglobin augmented with RHuEPO therapy) or as a blood salvage procedure during the operation, has been shown to be effective in certain operations. Nevertheless, autologous transfusion is not universally adopted in the UK and is expensive to implement. There is increasing evidence that RHuEPO can minimise blood transfusion in patients whose surgical procedure, for example cardiothoracic surgery or orthopaedic surgery, may cause up to a 20% loss of total blood volume. Furthermore, a recent study has demonstrated that in patients who were not eligible for autologous donation, a low dose of RHuEPO (150 IU/kg/week) given 3–4 weeks before surgery reduced the blood transfusion requirement by nearly 50%.

Anaemia associated with HIV infection

Up to two thirds of patients suffering from AIDS have anaemia, particularly those who are receiving zidovudine therapy. Treatment with RHuEPO, given either as a weekly dose (24 000–48 000 U) or as a thrice weekly administration (100–200 U/kg), corrects anaemia, improves the patient’s quality of life when baseline serum erythropoietin is <500 mU/ml, and improves survival. It has been suggested that the target haemoglobin should be maintained at 120 g/l and 110 g/l in males and females respectively.
OTHER POTENTIAL APPLICATIONS FOR RHuEPO

Autoimmune diseases

Anaemia is common in rheumatological disorders, in particular rheumatoid arthritis. This is usually due to anaemia of chronic disease. Pure red cell aplasia, a rare but recognised complication of systemic lupus erythematosus, could further exacerbate the anaemia. Other complications, such as severe blood loss and malabsorption, are particularly prominent in inflammatory bowel diseases. The RHuEPO therapy has been shown to be effective in controlling these immune associated conditions.79–84

Haemolysis

The fall of haemoglobin as a result of RBC disorders, such as hereditary spherocytosis and haemoglobinopathies, or due to mechanical damage, such as cardiac valve dysfunction, can be controlled, at least temporarily, by the use of RHuEPO.79–81

Acute renal failure

In murine model of ischaemic acute renal failure, RHuEPO has been found capable to rapidly reverse the associated anaemia, accelerate functional recovery of the kidneys, and reduce mortality.77–78 Furthermore, RHuEPO may offer renoprotection in cisplatin induced acute renal failure and accelerates renal recovery.78–80 Clinical studies to evaluate these important findings are warranted.

Critically ill patients

Patients in intensive care regularly require blood transfusion. Patients who are anaemic have an inappropriately low endogenous serum erythropoietin.86 A recent prospective, multicentre, randomised study has demonstrated that RHuEPO therapy (initiated on 300 U/kg subcutaneously from day 3 for five consecutive days followed by an alternate day administration until the packed cell volume reached 38%) reduced the requirement of blood transfusion by 50%. Furthermore, there were no significant differences in both mortality and frequency of adverse events when compared with the control groups.87

Neuroprotection

Based on the results from murine model, the use of RHuEPO has been shown to limit the degree of ischaemic cerebral damage and spinal cord injury, together with expediting neurological recovery.88–90 Ehrenreich and coworkers have demonstrated the beneficial effects of administering RHuEPO in patients with acute ischaemic stroke.91 When given within five hours of onset of symptoms, intravenous RHuEPO (33 000 IU daily for three days) was associated with a significant improvement in both functional activity and clinical outcome. When compared with the controls, the RHuEPO group had a strong trend on reduction in infarct size. Furthermore, no safety concerns were identified in the study. The results of the study offer potential value to patients in whom thrombolytic therapy is contraindicated. Whether RHuEPO could add value to the thrombolytic therapy in treating acute ischaemic stroke remains to be determined.

Congestive cardiac failure

Although anaemia is commonly encountered in congestive cardiac failure, its clinical significance is less appreciated. Silverberg and colleagues have correlated the clinical importance of anaemia in congestive cardiac failure.92 Firstly, the severity of anaemia increases with the worsening of congestive cardiac failure. Secondly, anaemia is an independent risk factor for cardiac death (nearly doubling the mortality rate). Thirdly, many causes of anaemia may coexist in this setting. For instance, iron deficiency secondary to poor nutrition; suboptimal erythropoietin activity due to production deficiency (for example, angiotensin converting enzyme inhibitor), proteinuria (loss of erythropoietin) and increased activity of cytokines (for example, tumour necrosis factor-α), together with haemodilution due to an increased plasma volume, which all contribute to anaemia. Fourthly, the anaemia itself could lead to prolonged activation of the renin-angiotensin-aldosterone system, thus exacerbating the congestive cardiac failure. Renal function then deteriorates and the production of erythropoietin is reduced. Erythropoietin activity is further impaired due on an increased secretion of cytokines triggered by congestive cardiac failure. As a consequence, the anaemia is worsened and a vicious cycle is created (Cardio-Renal-Anaemia syndrome). Fifthly, the anaemia in congestive cardiac failure could be safely corrected by subcutaneous RHuEPO and intravenous iron, which results in ameliorating congestive cardiac failure, preventing the progression of chronic renal failure, reducing diuretic doses and hospitalisation, together with improving the quality of life. Finally, the authors have emphasised that the treatment of anaemia should be initiated early and the success of treatment requires a close cooperation between cardiologists and nephrologists.

The benefit of early anaemia treatment using subcutaneous RHuEPO (with intravenous iron) is supported by the results of a recent study involving both type 2 diabetes and non-diabetes suffered from moderate to severe resistant congestive cardiac failure.93 In addition to a significant improvement in both functional status and cardiac function, there was a marked reduction in hospitalisation, together with stabilisation of renal function.

AVOIDANCE OF BLOOD TRANSFUSION

Blood transfusion remains the mainstay for treating patients suffered from symptomatic anaemia. However, patients may refuse a blood transfusion because of personal preferences or religious reasons. Sometimes, due to the previous allosensitisation and the presence of rare RBC antigens, the procurement for sufficient units of compatible blood may not be feasible. Furthermore, the impending changes issued by the Department of Health on blood transfusion, including revision of blood donor eligibility and blood testing on new variant Creutzfeldt-Jakob disease, will severely affect the blood donor pool and further limit the availability of blood supply.94–95

Although RHuEPO therapy has been shown to be a suitable alternative for blood transfusion, the treatment is only applicable in non-acute or planned situations. In general, it takes at least 72 hours to detect a reticulocyte response and at least 10–14 days for any significant rise in haemoglobin. Other potential candidates of blood substitutes, for example recombinant haemoglobin, polymerised haemoglobin and perfluorocarbons, are currently being assessed.

In Jehovah’s Witnesses, RHuEPO has been successfully employed to avoid blood transfusion in various surgical conditions.
OPTIMISATION OF RHuEPO TREATMENT

In renal patients requiring dialysis, the concomitant use of intravenous iron, either intermittently or continuously, has been shown to reduce the RHuEPO dosage requirement to intravenous iron, either intermittently or continuously, has been shown to reduce the RHuEPO dosage requirement to maintain the target haemoglobin.

Box 6: Contributing factors which affects the response to RHuEPO

<table>
<thead>
<tr>
<th>Therapeutic</th>
<th>Pathological</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Non-compliance</td>
<td>• Iron deficiency.</td>
</tr>
<tr>
<td>• Suboptimal treatment: “faulty” delivery, incorrect dosage of RHuEPO, under-dialysis.</td>
<td>• B12/folate deficiency.</td>
</tr>
<tr>
<td></td>
<td>• Infection.</td>
</tr>
<tr>
<td></td>
<td>• Inflammation.</td>
</tr>
<tr>
<td></td>
<td>• Blood loss: haemorrhage, haemolysis (intravascular/extravascular).</td>
</tr>
<tr>
<td></td>
<td>• Metabolic disorder—for example, secondary hyperparathyroidism.</td>
</tr>
<tr>
<td></td>
<td>• Extensive bone marrow involvement: malignant cells, fibrosis, aluminium toxicity.</td>
</tr>
<tr>
<td></td>
<td>• Erythropoietin antibody ± pure red cell aplasia.</td>
</tr>
</tbody>
</table>

MISUSE OF RHUEPO (“BLOOD DOPING”)

An increase in haemoglobin above normal physiological values has been shown to enhance physical endurance presumably as a result of increased oxygenation in the blood. As some athletes use RHuEPO as a “performance enhancer”, the International Olympic Committee has classified RHuEPO as a banned substance. Unfortunately, the detection of RHuEPO still remains difficult. Although various parameters have been employed (for example, reticulocyte haemoglobin, serum transferrin receptor, packed cell volume, etc), none of them are reliable or reasonably sensitive. The use of electrophoretic analysis on the glycosylation pattern of serum erythropoietin may be able to distinguish the endogenous from the recombinant form. However, the procedure is time consuming and is not universally available.

UNSATISFACTORY RESPONSE TO RHUÉPO TREATMENT

Failure to respond to RHuEPO therapy could be defined as haemoglobin increases of <10 g/l after a four week standard dosage treatment. However, the definition of resistance to RHuEPO therapy varies among different settings. For instance, in renal anemia, resistance to RHuEPO is defined by a failure to attain the target haemoglobin while receiving >300 IU/kg/week or a continued need for such a dosage to maintain the target haemoglobin. In the haematology/oncology setting, resistance to RHuEPO therapy is regarded as no satisfactory haemoglobin increase of >10 g/l despite a four week high dose RHuEPO (900 IU/kg/week) therapy, in patients previously failed on a four week treatment with standard dosage (450 IU/kg/week). Nevertheless, it is important that other possible contributing factors are excluded (box 6).

Box 7: Predictive factors for response to RHuEPO therapy

<table>
<thead>
<tr>
<th>RBC parameters</th>
<th>Cytokines</th>
<th>Iron status</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Haemoglobin level.</td>
<td>• Serum erythropoietin level.</td>
<td>• Serum ferritin level.</td>
</tr>
<tr>
<td>• Packed cell volume.</td>
<td>• Tumour necrosis factor-α.</td>
<td>• Transferrin saturation.</td>
</tr>
</tbody>
</table>

Box 8: Clinical features of PRCA associated with RHuEPO treatment

| • Persistent or worsening anaemia despite maximised RHuEPO therapy. |
| • Median age of presentation: 61 years. |
| • Male to female ratio: 2 to 1. |
| • Median duration of RHuEPO treatment to time of diagnosis: seven months. |

Box 8: Clinical features of PRCA associated with RHuEPO treatment

Despite the initiation RHuEPO treatment dosage in malignancy being five times higher than that of renal, the average response is only 50% (compared with >90% in patients with chronic renal failure). Furthermore, RHuEPO therapy is expensive and will further impose pressure on the restricted hospital funding. As a consequence, guidelines with emphasis on factors such as patient selection, type of chemotherapy employed, and utilisation of specific predictive factors (box 7) are required to rationalise the use of RHuEPO. These guidelines will assist in providing treatment to appropriate patients and minimise the economic impact on widespread use of RHuEPO.

As RHuEPO therapy accelerates erythropoiesis, a functional iron deficiency (a condition in which the iron store in the body remains normal but the rate of iron supply fails to keep pace with the rate of accelerated utilisation) will ensue. Therefore, iron supplementation is strongly recommended during RHuEPO treatment and the iron status should be regularly monitored.

COMPLICATIONS OF RHUEPO TREATMENT

The most common side effect of RHuEPO therapy is “flu-like” illness. It is generally mild, subsides within 24 hours, and responds well on simple supportive treatment. Hypertension and thrombosis have also been reported. They are associated with a rapid rise in haemoglobin/packed cell volume during RHuEPO treatment. Clinical vigilance will minimise the occurrence of these problems. Other side effects such as allergic/anaphylactoid reactions, seizure, hyperkalaemia, and thrombocytosis have been rarely reported.

A serious but very rare complication, known as pure red cell aplasia (PRCA), has recently been reported in renal patients receiving RHuEPO treatment (box 8). The management of
PRCA associated with RUHUEPO therapy includes confirming PRCA by bone marrow biopsy, discontinuing the RUHUEPO, initiating immunosuppressants with or without intravenous immunoglobulins, and blood support if required. It is important to report the complication to the Committee on Safety of Medicine (via the yellow card system) and to the manufacturer.

Although PRCA is a very rare complication associated with RUHUEPO treatment, it has significant implications concerning the use of RUHUEPO in clinical practice. Regular assessment of the clinical status of the patients, together with monitoring the haemoglobin level and the reticulocyte count during RUHUEPO therapy, is therefore strongly recommended.

CONCLUSION

The use of RUHUEPO has undoubtedly altered the traditional management of renal anaemia. Its therapeutic benefit has been explored in other clinical areas. Nevertheless, RUHUEPO is an expensive treatment and not every patient will benefit from it. Any contributory and treatable causes of anaemia must be excluded before the initiation of RUHUEPO therapy. In malignancy, it is advisable that RUHUEPO therapy is targeted to the subgroup of patients who is most likely to respond. Iron supplementation is recommended as RUHUEPO therapy accelerates erythropoiesis causing a functional iron deficiency.

Based on the effect of RUHUEPO on its receptor, investigations have been focused on searching for alternatives to enhance and stimulate erythropoiesis. In the future, we are likely to envisage new development which optimises and maximises erythropoiesis, thus shifting the paradigm of anaemia management.

Authors' affiliations

T Ng, Phase One Clinical Trials Unit Ltd, Plymouth, UK
G Marx, Sydney Haematology Oncology Clinic, Hornsby, New South Wales, Australia
T Littlewood, Department of Haematology, John Radcliffe Hospital, Oxford, UK
I MacDougall, Department of Renal Medicine, King's College Hospital (Dulwich), London, UK

REFERENCES


www.postgradmedj.com


